OncoMatch/Clinical Trials/NCT07413354
Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
Is NCT07413354 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Tislelizumab plus Huaier granule for hepatocellular carcinoma (hcc).
Treatment: Tislelizumab plus Huaier granule — This study is a single-arm prospective clinical trial that enrolled 94 patients with unresectable hepatocellular carcinoma(HCC) who received first-line treatment with tislelizumab combined with Huaier granule. By comparing the objective response rate (ORR) and other data with those from the historical Rational 301 study, the study aims to explore the efficacy and safety of tislelizumab combined with Huaier granule as a first-line treatment for unresectable HCC, as well as its potential to improve patients' quality of life and alleviate HCC-related symptoms.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage BCLC STAGE C, BCLC STAGE B DISEASE THAT IS UNSUITABLE FOR LOCOREGIONAL THERAPY OR HAS PROGRESSED AFTER LOCOREGIONAL THERAPY, AND IS NOT ELIGIBLE FOR CURATIVE TREATMENT (BCLC)
BCLC stage C, or BCLC stage B disease that is unsuitable for locoregional therapy or has progressed after locoregional therapy, and is not eligible for curative treatment
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
No prior systemic therapy for HCC
Cannot have received: local liver therapy (transarterial chemoembolization, transarterial embolization, hepatic arterial infusion, radiotherapy, radioembolization, ablation)
Exception: allowed if completed >28 days before enrollment
Prior local liver therapy (e.g., transarterial chemoembolization, transarterial embolization, hepatic arterial infusion, radiotherapy, radioembolization, or ablation) within 28 days before enrollment
Cannot have received: immunotherapy (interleukin, interferon, thymosin)
any immunotherapy (e.g., interleukin, interferon, thymosin, etc.) within 28 days before enrollment
Lab requirements
Liver function
child-pugh class a liver function within 7 days prior to randomization
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify